Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535672 | 0.88 | KDM4E (0.60) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL4504641 | 0.85 | SMN1; SMN2 (0.65) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL20535057 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL11124986 | 0.83 | CA12 (0.54) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL31215786 | 0.82 | NPC1 (0.50) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL13787073 | 0.82 | CASP6 (0.62) | KDM4ESMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL12660566 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL13102601 | 0.80 | MAPT (1.00) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL1852815 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL1851374 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149239-A1 | HETEROAROMATIC CYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2024-07-18 | — | — | WO | disclosed |
| WO-2018189683-A1 | BENZOFURAN DERIVATIVES FOR USE AS AMPK ACTIVATORS | UNIVERSITA' DI PISA (IT) | 2018-10-18 | — | — | WO | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | KDM4E 1855/4885ALDH1A1 315/4885HSD17B10 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.